Infex Therapeutics has combined forces with medical research charity, LifeArc, to develop the next generation of drugs to treat serious infections caused by superbugs.

The collaboration will see Infex Therapeutics develop innovative antimicrobial compounds against LifeArc’s drug targets, in particular to tackle critical-priority Gram-negative bacteria.

Dr Peter Jackson, executive director of Infex Therapeutics, said, “We are delighted to announce this important collaboration with LifeArc, which could make a significant contribution to re-invigorating the pipeline of new products to treat drug-resistant infections.”

Katy Kettleborough, Head of Biology at LifeArc said “We are looking forward to working with Infex Therapeutics on our early discovery targets and value their expertise in this space”

It is anticipated that a number of disease targets will be progressed through the collaboration.


About LifeArc

LifeArc is a self-funded medical research charity. Our mission is to advance translation of early science into health care treatments or diagnostics that can be taken through to full development and made available to patients. We have been doing this for more than 25 years and our work has resulted in a diagnostic for antibiotic resistance and four licensed medicines.

Our success allows us to explore new approaches to stimulate and fund translation. We have our own drug discovery and diagnostics development facilities, supported by experts in technology transfer and intellectual property who also provide services to other organisations. Our model is built on collaboration, and we partner with a broad range of groups including medical research charities, research organisations, industry and academic scientists. We are motivated by patient need and scientific opportunity.

Two funds help us to invest in external projects for the benefit of patients: our Philanthropic Fund provides grants to support medical research projects focused on the translation of rare diseases research and our Seed Fund is aimed at start-up companies focussed on developing new therapeutics and biological modalities.

About Infex Therapeutics

We acquire, develop and license innovative drugs to treat pandemic infections. We have expanded to develop a broader portfolio of new therapies to meet the rising burden of critical priority infectious disease. Based at Alderley Park in the North West of England, our work addresses unmet patient needs and will bring new portfolio of drugs into clinical trials to treat patients suffering from life-threatening infections.